Search filters

Filters
Clear All

Phase

  • 4
  • 6
  • 1
  • 1
  • 14
  • 4
  • 14

Found 14 Brain Tumor trials

A listing of Brain Tumor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Glioblastoma adaptive  global  innovative learning environment
18 years - 99 years
All genders
Phase 2
This research study aims to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. The investigational drugs that will be used in this research study are temozolomide for newly diagnosed glioblastoma …
 ONC201 in recurrent high-grade glioma
18 years - 99 years
All genders
Phase 2
This is a phase II, open-label study of ONC201 in adults with recurrent high- grade glioma. Subjects for this study will be recruited from the patient population that present to the Penn Brain tumor center- Department of Neurosurgery or Department of Medicine division of Hematology/ Oncology for evaluation and treatment …
18 years - 99 years
All genders
Phase 1
Interventional
The purpose of this study is to test the ability of a new drug, BGB324, to get into the brain tumor (e.g.by crossing the blood brain barrier) in patients with recurrent glioblastoma who require surgery.
 ImmuneSense Study- Safety and Efficacy of IGV-001  an Autologus Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R  in Newly Diagnosed Patients With Glioblastoma Multiforme
18 years - 99 years
All genders
Phase 2
The purpose of this study is to see how safe the study medicine, IGV-001 plus standard of care (SOC), is and to compare IGV-001 with placebo (only standard of care) to see if it works in slowing GBM tumor regrowth. Participants for this study will be recruited from the patient …
 Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naive and Bevacizumab Resistant Recurrent Glioblastoma
18 years - 99 years
All genders
Phase 2
This is a multicenter, open-label, phase II trial of pembrolizumab plus re-irradiation among recurrent glioblastoma patients enrolled to two parallel, non-comparative treatment arms including patients who are bevacizumab naïve (Arm A, n=30) and patients who are bevacizumab-resistant (Arm B, n=30). All subjects must have histologically confirmed World Health Organization (WHO) …
 Evaluation of Vascular Health Profile in Predicting Venous Thromboembolism
1 years - 99 years
All genders
The main goal of this study is to utilize previously validated cytometric markers of to identify cancer patients at high risk of VTE. The primary outcome will be DVT or pulmonary embolism (PE). Patients with pancreatic and brain cancer will be enrolled as these patients are known to have higher …
 AGIOS
18 years - 99 years
All genders
Phase 3
Normal 0 false false false EN-US X-NONE X-NONE  This research study is a phase 3, double-blind clinical trial to assess the efficacy of Agios versus placebo in subjects with residual or recurrent Grade 2 oligodendroglioma and astrocytoma with an IDH1 or IDH2 mutation who have undergone surgery as their only …
99 years or below
All genders
Phase 1
Interventional
This study is being done to determine how well the study drug, BGB-290, gets into the brain tumor and to confirm if we can continuously and safely give BGB-290 and temozolomide as a combination treatment after surgery. We are testing a dose of temozolomide once a day combined with the …
 A Randomized Multicenter Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
18 years - 98 years
All genders
Phase 2
The BBI-DSP-7888-201G trial is designed to compare the overall survival (OS) between treatment with DSP-7888 Dosing Emulsion plus bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following initial therapy. This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study. Approximately 200 patients …
18 years - 75 years
All genders
Phase 2
This is a multicenter, randomized, open-label study of Toca 511 and Toca FC versus standard of care (SOC) that comprises Investigators choice of either single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of glioblastoma or anaplastic astrocytoma. …
1 - 10 of 14